NEW YORK (GenomeWeb) – Grail said today that it has begun a clinical trial, STRIVE, for its next-generation sequencing-based blood test for early-stage cancer detection. The firm will collaborate with the Mayo Clinic and Sutter Health to enroll up to 120,000 women at the time when they receive a mammogram. The goal will be to train and validate the test.

The STRIVE study will enroll women at the Mayo and throughout the Sutter Health system in Northern California.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.